Jan, 06 2020 09:57 JST
Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China
TOKYO, Jan, 06 2020 - (JCN Newswire) - Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic name perampanel) for use in the adjunctive treatment of partial-onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.
In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom are affected by partial-onset seizures. About 40% of patients with partial-onset seizures require adjunctive treatment(1). As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs(2), this is a disease with significant unmet medical needs. Fycompa was designated for Priority Review by the National Medical Products Administration due to its significant clinical benefits compared to existing treatments after the submission in September 2018 and was approved on September 29, 2019.
Fycompa is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research Laboratories. In the United States and Europe, a new oral suspension formulation has been approved and is being marketed. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes.
Fycompa has been approved in over 65 countries around the world as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in over 60 countries as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.
Eisai considers neurology including epilepsy, a therapeutic area of focus. With this launch of Fycompa in China, Eisai pursues our mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.
(1) Clinical Guideline 2015 in China.
(2) "The Epilepsies and Seizures: Hope Through Research. What are the epilepsies" National Institute of Neurological Disorders and Stroke, accessed May 24, 2016, https://bit.ly/39BKqDT
About Fycompa (perampanel)
Fycompa is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa is available in tablet form to be taken once daily orally at bedtime. In addition, an oral suspension formulation has been approved and marketed in the United States and in Europe. To date, Fycompa has been used to treat more than 270,000 patients worldwide across all indications.
Fycompa is currently approved in more than 65 countries and territories, including the United States, Japan, in Europe and in Asia as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in more than 60 countries, including the United States, Japan, in Europe and in Asia for treatment as adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older. In Japan, a supplementary new drug application has been filed seeking approval of Fycompa for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a fine granule formulation. In Europe, an application has been submitted seeking the additional approval of Fycompa for adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) or primarily generalized tonic-clonic seizures in pediatric patients with epilepsy.
Furthermore, Eisai is conducting a global Phase III clinical study (Study 338) for the agent in patients with seizures associated with Lennox-Gastaut syndrome.
Epilepsy affects approximately 9 million people in China, 6 million people in Europe, 3.4 million people in the United States, 1 million people in Japan, and approximately 60 million people worldwide. As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs2, this is a disease with significant unmet medical need.
Epilepsy is broadly categorized by seizure type, with partial-onset seizures accounting for approximately 60% of epilepsy cases and generalized seizures accounting for approximately 40%. In a partial-onset seizure, an abnormal electrical disturbance occurs in a limited area of the brain, and may subsequently spread throughout the brain, becoming a generalized seizure (known as a secondarily generalized seizure). In a generalized seizure, abnormal electrical disturbances occur throughout the brain and can be followed by a loss of consciousness or physical symptoms manifested throughout the whole body.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.
For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.
Public Relations Department,
Eisai Co., Ltd.
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
Honda to Make Changes to its Organizational and Operational Structures (effective April 1, 2020)
Feb 18, 2020 16:07 JST
Honda Establishes a New Company, Honda Mobility Solutions Co., Ltd., Responsible for Mobility Service (MaaS) Business in Japan
Feb 18, 2020 15:32 JST
Fujitsu Granted Japan's First Private 5G License
Feb 18, 2020 14:53 JST
2020 Kicks Off in Texas for TOYOTA GAZOO Racing
Feb 17, 2020 19:59 JST
NEC and Cisco to Provide Network Equipment with Enhanced Supply Chain Management
Feb 17, 2020 15:09 JST
Evans Wins, Rovanpera on the Podium with Stunning Drives in the Toyota Yaris WRC
Feb 17, 2020 09:14 JST
MHI: Charter of Trust Partners Decide on Further Measures for More Cybersecurity
Feb 14, 2020 16:52 JST
Toyota Mobility Foundation Introduces Global Next-Gen Urban Development & Traffic Management Challenge with MDEC
Feb 13, 2020 17:19 JST
SDK Announces 2019 Consolidated Financial Results
Feb 13, 2020 17:00 JST
SDK to Change Part of its Articles of Incorporation
Feb 13, 2020 17:00 JST
SDK Announces Partial Amendment to Earlier News Release on "Changes in Representative Director and Other Members of Management"
Feb 13, 2020 17:00 JST
SDK Records Impairment Loss (Extraordinary Loss)
Feb 13, 2020 17:00 JST
MHPS Signs Agreement with U.S. Firm KBR to Expand Sales of SDA Pitch-fired Power Plants
Feb 13, 2020 16:59 JST
Honda to Begin Sales of All-new Fit in Japan
Feb 13, 2020 16:21 JST
TANAKA to Exhibit at FC EXPO 2020
Feb 13, 2020 11:00 JST
NEC and Mavenir Collaborate to Deliver 5G Open vRAN Solution
Feb 13, 2020 09:20 JST
Honda Aircraft Company's Debut of HondaJet Elite at Singapore Airshow 2020
Feb 12, 2020 18:26 JST
SDK Develops AI-Based Image Analysis System to Improve Spherical Alumina Production
Feb 12, 2020 12:30 JST
Fujitsu's AI Image Analysis Solution Measure and Evaluate Digital Signage User Experience, Vitalize Cities
Feb 12, 2020 11:52 JST
MHI Ships its 1000th Boeing 787 Dreamliner Composite-Material Wing Box
Feb 10, 2020 18:04 JST